Opdivo + Yervoy showed durable, long-term survival in NSCLC

CAR-T Digest - August 2020

Weekly Digest - 03-09 Jun 2023

Jun 4, 2023: Nivolumab + Ipilimumab (oral) / NSCLC / BMS: Nivolumab + Ipilimumab along with chemo demonstrated durable, long-term survival in NSCLC patients

At ASCO 2023, BMS announced Nivolumab + Ipilimumab along with 2 cycles of chemo demonstrated durable, long-term survival in previously treated patients with NSCLC
The approval is based on 4-year follow-up results from the Phase 3 CheckMate -9LA trial evaluating Nivolumab 360 mg Q3W + Ipilimumab 1 mg/kg Q6W combined with chemo (two cycles) compared to chemo alone
PD-L1 <1%: OS rate of 23% for those treated with the dual immunotherapy-based combination vs. 13% for chemotherapy alone, representing a 34% reduction in the risk of death
Squamous histology: Among those with squamous histology, twice the number of patients treated with Opdivo + Yervoy with chemo were alive at 4 years compared to those who received chemotherapy alone (20% vs. 10%, respectively)
In this group, the dual immunotherapy combination reduced the risk of death by 36% compared to chemotherapy alone
No new safety signals were observed